Supplementary Figure S5 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30&lt;sup&gt;+&lt;/sup&gt; Malignancies